IBEX vs RPD
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
IBEX exhibits exceptional fundamental health with a Piotroski F-Score of 8/9, indicating strong financial stability and operational efficiency. The stock is currently trading at $27.49, which is essentially at its Graham Number ($27.9) and significantly below its growth-based intrinsic value of $88.79. Despite a bearish technical trend and recent insider selling by the CEO, the combination of a low P/E (9.13), high ROE (33.65%), and robust earnings growth (45.6% YoY) presents a compelling value opportunity.
RPD exhibits a precarious financial profile characterized by a stable but mediocre Piotroski F-Score of 4/9 and a dangerously high Debt/Equity ratio of 6.26. While valuation metrics like the PEG ratio (0.27) and Forward P/E (3.61) suggest the stock is deeply undervalued, this is offset by stagnant revenue growth (0.50%) and a catastrophic long-term price collapse (-93.3% over 5 years). The disconnect between the Intrinsic Value ($10.62) and the current price reflects significant market skepticism regarding the company's solvency and growth trajectory.
Compare Another Pair
Related Comparisons
IBEX vs RPD: Head-to-Head Comparison
This page compares IBEX Limited (IBEX) and Rapid7, Inc. (RPD) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.